As TAVI Advances, Adjunctive Devices Multiply
As researchers work to more fully understand the risks and durability of transcatheter aortic heart valve implantation (TAVI) procedures, device innovators are already attempting to engineer solutions to some of the more obvious areas of unmet need.
You may also be interested in...
Brief summaries of recent medtech market and industry developments. This month we cover KCI's shift to private status, J&J's exit from drug-eluting stents, safety concerns about Edwards' Sapien TAVI device, and the MoneyTree 2Q2011 report on medtech venture financings.
In this week's podcast edition of Five Must-Know Things: safety debate as more lecanemab data reported; amyloid discussions continue at Alzheimer’s meeting; China COVID unrest affect country’s biotech sector; and Merck’s CMO talks about post-Keytruda plans.
Demand-related shortages are a relatively new problem, but the FDA maintains their tools can prevent or end them.